Cooper Companies (COO) delivered solid Q4 FY2025 results, with revenue rising 4.6% year-over-year to a record $1.065 billion and non-GAAP EPS increasing 11% to $1.15. CooperVision grew 3.2% organically to $710 million, driven by MyDay momentum, while CooperSurgical grew 3.9% organically to $356 million. Operating margins expanded to 27%, and free cash flow was strong at $150 million. The company announced a formal strategic review to unlock shareholder value and a board leadership transition. For FY2026, management guides for revenue of $4.30-$4.34 billion (4.5-5.5% organic growth) and EPS of $4.45-$4.60, supported by $50 million in reorganization savings and robust MyDay traction, though gross margins face headwinds from tariffs and product mix.
| Metric | Value | Change |
|---|---|---|
| Revenue | $1.065 billion | +4.6% YoY |
| Organic Revenue Growth | 3.4% | N/A |
| Non-GAAP EPS | $1.15 | +11% YoY |
| Operating Margin | 27% | Increased |
| Free Cash Flow | $150 million | Strong |
| CooperVision Revenue | $710 million | +3.2% Organic |
| CooperSurgical Revenue | $356 million | +3.9% Organic |
Cooper announced a formal strategic review to explore alternatives for unlocking shareholder value, alongside the transition of the Chair role to independent director Colleen Jay. This signals a proactive approach to addressing potential undervaluation and could lead to significant corporate action, such as a breakup or sale, which has been a point of investor interest.
Management highlighted the 'accelerated global rollout' of the MyDay portfolio and 'robust momentum' in winning private label contracts, particularly in the US and Europe. New product launches like MyDay Energous and MyDay MySite are expected to drive growth, particularly in the back half of FY2026, reinforcing the shift toward premium daily silicone hydrogel lenses.
The board authorized a $2 billion share repurchase plan and raised the 2026-2028 free cash flow target to over $2.2 billion. Management committed to allocating roughly two-thirds of free cash flow to buybacks, prioritizing shareholder returns and signaling confidence in the company's cash generation capabilities.
The company completed a significant reorganization expected to deliver $50 million in annual pretax savings starting in FY2026. Management emphasized the use of AI to streamline back-office functions and improve productivity, which supports operating margin expansion despite revenue mix headwinds.
MiSight delivered strong growth of 37% in Q4, and management expects 20-25% growth in FY2026. Upcoming launches in Japan and Europe (MyDay MiSight) position Cooper to capitalize on the growing myopia management market, leveraging its clinical data leadership.
CooperVision faced a 28% decline in China in Q4 due to weakness in low-margin e-commerce channels. Management explicitly stated they 'do not chase revenues at all cost' and are refusing to engage in aggressive pricing, which could lead to sustained market share loss in this key region.
Gross margins declined to 66.2% in Q4 and are expected to face further headwinds in FY2026 due to a shift toward lower-margin daily silicone hydrogel lenses (MyDay) and tariffs. This mix shift creates a tension between revenue growth and profitability that investors must monitor.
Asia Pac growth was flat for the quarter, a significant deceleration from previous years. Management attributed this to specific channel issues and pricing discipline, but it highlights a geographic weakness that offsets strength in the Americas and EMEA.
While the strategic review is a potential catalyst, it introduces execution risk and uncertainty. Management noted that a separation would create 'dis-synergies' and be negative from a tax perspective, suggesting a breakup might not be the optimal path despite investor pressure.
Overall: Management conveyed a confident and decisive tone, emphasizing disciplined execution and a strong commitment to shareholder returns. They were transparent about challenges in China but expressed optimism regarding new product launches and the strategic review process. The demeanor shifted from purely operational in prepared remarks to defensive yet assured during the Q&A regarding margins and strategic alternatives.
Confidence: HIGH - Management raised free cash flow targets, authorized a massive $2 billion buyback, and beat consensus estimates. Their language was specific regarding cost savings and product pipelines, indicating high visibility into future performance.
$4.30 billion - $4.34 billion (4.5-5.5% Organic)
$4.45 - $4.60
$575 million - $625 million
4.5% - 5.5% Organic
4% - 5% Organic
Hedging & Uncertainty: Management employed hedging language primarily around guidance and market assumptions to maintain credibility and set achievable targets. Phrases like 'assuming the market grows,' 'we're maintaining conservatism,' and 'I'd be really surprised if we're not' suggest a strategy to under-promise and over-deliver. They also hedged on the strategic review, stating they are 'looking at alternatives' without committing to a specific outcome, which preserves flexibility but creates near-term uncertainty.
We're taking a serious look at all the different alternatives that are out there... ensure that we're driving long term shareholder value. - Al White, President and CEO
We do not chase revenues at all cost. We would never do that. - Al White, President and CEO
Momentum is robust, we're seeing increasing bidding activity... - Al White, President and CEO
We're maintaining conservatism to avoid having guidance be too back end loaded. - Al White, President and CEO
I think that's good hygiene. I think that's important to do. - Al White, President and CEO
We're highly focused on driving long-term shareholder value. - Al White, President and CEO
Analyst Sentiment: Analysts were highly engaged, focusing heavily on the implications of the strategic review, specifically the potential for a breakup of the company. There was also skepticism regarding the margin outlook given the mix shift and the sustainability of growth in Asia Pac.
Management Responses: Al White was firm on the company's pricing discipline in China ('we do not chase revenues at all cost') and non-committal but thorough regarding the strategic review process. Brian Andrews provided detailed explanations on margin mechanics to reassure investors about earnings power despite gross margin declines.
Strategic alternatives and potential breakup of CooperVision and CooperSurgical.
China market dynamics and the decision to avoid aggressive pricing in low-margin e-commerce channels.
Gross margin headwinds driven by product mix (shift to daily silicone hydrogel) and tariffs.
MyDay private label contract momentum and the 'stair step' growth trajectory.
Fertility market trends and consumer spending in Asia Pac.
Cooper Companies is executing a multi-faceted value creation strategy that combines operational efficiency with capital discipline. The core business is stabilizing, driven by the MyDay portfolio and a reorganization yielding $50 million in annual savings. The formal strategic review acts as a significant near-term catalyst to address any valuation discount, potentially leading to a sale or breakup. While margin headwinds from product mix and China weakness persist, the strong free cash flow generation ($2.2B target '26-'28) and aggressive share buybacks ($2B authorization) provide a solid floor for the stock. The shift to higher-growth, premium products like MyDay MiSight positions the company well for long-term share gains.
Management cited tariffs as a specific driver of gross margin decline in Q4 and a continued headwind for FY2026.
Consumer spending remains tight, particularly in Asia Pac, impacting fertility clinic cycles and demand for medical devices.
Potential Fed rate cuts could reduce interest expense by roughly $2 million in FY2026.